China SXT Pharmaceuticals (SXTC) Total Current Liabilities (2018 - 2025)
Historic Total Current Liabilities for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $6.0 million.
- China SXT Pharmaceuticals' Total Current Liabilities fell 6194.24% to $6.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.0 million, marking a year-over-year decrease of 6194.24%. This contributed to the annual value of $6.0 million for FY2025, which is 3246.35% down from last year.
- China SXT Pharmaceuticals' Total Current Liabilities amounted to $6.0 million in Q3 2025, which was down 6194.24% from $6.0 million recorded in Q1 2025.
- China SXT Pharmaceuticals' Total Current Liabilities' 5-year high stood at $18.6 million during Q1 2021, with a 5-year trough of $6.0 million in Q3 2025.
- Over the past 5 years, China SXT Pharmaceuticals' median Total Current Liabilities value was $9.1 million (recorded in 2023), while the average stood at $11.2 million.
- As far as peak fluctuations go, China SXT Pharmaceuticals' Total Current Liabilities soared by 7026.26% in 2024, and later tumbled by 6194.24% in 2025.
- Quarter analysis of 5 years shows China SXT Pharmaceuticals' Total Current Liabilities stood at $8.9 million in 2021, then fell by 17.87% to $7.3 million in 2022, then rose by 26.17% to $9.2 million in 2023, then soared by 70.26% to $15.7 million in 2024, then plummeted by 61.94% to $6.0 million in 2025.
- Its Total Current Liabilities was $6.0 million in Q3 2025, compared to $6.0 million in Q1 2025 and $15.7 million in Q3 2024.